Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen

Journal of Health, Population and Nutrition

Volumn 28, Issue 1, 2010, Pages 7-13

  Green, E ^a,b   Obi, C L ^c   Nchabeleng, M ^d   de Villiers, B E ^d   Sein, P P ^d   Letsoalo, T ^d   Hoosen, A A ^d   Bessong, P O ^a   Ndip, R N ^b,e  

^a UNIVERSITY OF VENDA   (South Africa)

^b UNIVERSITY OF FORT HARE   (South Africa)

^c WALTER SISULU UNIVERSITY   (South Africa)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e UNIVERSITY OF BUEA   (Cameroon)

Author keywords

Drug resistance; Microbial; Mycobacterium tuberculosis; Risk factors; South Africa; Tuberculosis

Indexed keywords

MYCOBACTERIUM TUBERCULOSIS;

ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RETREATMENT; RISK FACTOR; SOUTH AFRICA; TUBERCULOSIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RETREATMENT; RIFAMPIN; RISK FACTORS; SOUTH AFRICA; STREPTOMYCIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 77951222268     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause? J R Soc Promot Health 2002;122:78-81.
2. World Health Organization. Global tuberculosis control surveillance, planning, financing: WHO report 2007. Geneva: World Health Organization, 2007. 270 p. (WHO/HTM/TB/2007.376).
3. World Health Organization. Seventh meeting [of the] Strategic and Technical Advisory Group for Tuberculosis (STAG-TB): report on conclusions and recommendations, 11-13 June 2007, Geneva. Geneva: World Health Organization, 2007. 32 p.
4. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. Geneva: World Health Organization, 2009. 303 p. (WHO/ HTM/TB/2009.411).
5. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004;10:1111-6.
6. Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 2007;196:S1-3.
7. World Health Organization. Global tuberculosis control 2008: surveillance, planning and financing: WHO report 2008. Geneva: World Health Organization, 2008. 294 p. (WHO/HTM/TB/2008.393).
8. Ani AE, Idoko J, Dalyop YB, Pitmang SL. Drug resistance profile of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria. Trans R Soc Trop Med Hygi 2009;103:67-71.
9. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med 2007;4:e50.
10. World Health Organization. Report of the meeting of the WHO Global Task Force on XDR-TB. Geneva: World Health Organization, 2006. 23 p. (WHO/HTM/ TB/2006.375).
11. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
12. World Health Organization. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on anti-tuberculosis drug resistance surveillance, 1994-1997. Geneva: World Health Organization, 1997. 227 p. (WHO/TB/97.229).
13. Fattorini L, Migliori GB, Cassone A. Extensively drugresistant (XDR) tuberculosis: an old and new threat. Ann Ist Super Sanita 2007;43:317-9.
14. Ait-Khaled N, Enarson DA. Tuberculosis: a manual for medical students. Geneva: World Health Organization, 2003. 141 p. (WHO/CDS/TB/99.272).
15. Cohen T, Sommers B, Murray M. The effects of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003;3:13-21.
16. Velayati AA, Masjedi MR, Mohammadi M. Textbook of tuberculosis. Tehran: Markaz Nashr Daneshgahi, 1977:819-33 [Persian].
17. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997. 186 p. (WHO/TB/ 96.210(rev)).
18. Zager EM, McNerney R. Mulridrug-resistant tuberculosis. BMC Infect Dis 2008;8:10.
19. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validatation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44:688-92.
20. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report. Geneva: World Health Organization, 2003. 229 p. (WHO/CDS/TB/2003.316).
21. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze et al. High prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008;12:635-44.
22. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54.
23. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
24. Montoro E, Lemus D, Echemedía M, Aemas L, González-Ochoa E, Llanes MJ et al. Drug-resistant tuberculosis in Cuba. Results of the three global projects. Tuberculosis (Edinb) 2006;86:319-23.
25. Quy HT, Cobelens FGJ, Lan NTN, Buu TN, Lambregts CSB, Borgdorff MW. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006;10:45-51.
26. Weyer K, Lancaster J, Balt E, Durrheim D. Tuberculosis drug resistance in Mpumalanga province, South Africa (abstract). Int J Tuberc Lung Dis 1998;2:S165.
27. South Africa. National Department of Health. Tuberculosis strategic plan for South Africa, 2007-2011. TB strategic plan report. Gauteng: National Department of Health, Government of South Africa, 2006. 66 p.
28. Han LL, Sloutsky A, Canale SR, Naroditskaya V, Shin SS, et al. Acquisition of drug resistance in multidrugresistant Mycobacterium tuberculosis during directlyobserved empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005;9:818-21.
29. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug-resistant tuberculosis in Europe: a systemic review. Thorax 2006;61:158-63.
30. Choi JC, Lim Y, Suh GY, Chung MP, Kim H, Kwon OJ et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-81.
31. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 2002;325;1282-6.
32. Han LL, Sloutsky A, Canales R, Naroditskaya V, Shin SS, Seung KJ et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005;9:818-21.
33. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug-resistant tuberculosis in Europe: a systemic review. Thorax 2006;61:158-63.
34. Choi JC, Lim Y, Suh GY, Chung MP, Kim H, Kwon OJ et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-81.
35. Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, Rüsch-Gerdes S et al. A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Micro Drug Resist 2005;11:62-7.